Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Rundquist Olof) > Real-world effectiv...

Real-world effectiveness of vedolizumab in inflammatory bowel disease : week 52 results from the Swedish prospective multicentre SVEAH study

Eriksson, Carl, 1981- (författare): Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Gastroenterology,Orebro Univ, Sweden; Karolinska Inst, Sweden

Rundquist, Sara, 1992- (författare): Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology,Orebro Univ, Sweden

Lykiardopoulos, Vyron (författare): Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken

visa fler...

Udumyan, Ruzan, 1971- (författare): Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Clinical Epidemiology and Biostatistic,Orebro Univ, Sweden

Karlén, Per (författare): Department of Internal Medicine, Danderyd Hospital, Stockholm, Sweden,Danderyd Hosp, Sweden

Grip, Olof (författare): Department of Gastroenterology, Skåne University Hospital, Malmö, Sweden,Skane Univ Hosp, Sweden

Söderman, Charlotte (författare): Karolinska Institutet

Almer, Sven (författare): Karolinska Institutet

Hertervig, Erik (författare): Department of Gastroenterology, Skåne University Hospital, Lund, Sweden,Skane Univ Hosp, Sweden

Marsal, Jan (författare): Department of Gastroenterology, Skåne University Hospital, Lund, Sweden,Skane Univ Hosp, Sweden

Gunnarsson, Jenny (författare): Department of Internal Medicine, Kungälv Hospital, Kungälv, Sweden,Kungalv Hosp, Sweden

Malmgren, Carolina (författare): Takeda Pharma AB, Stockholm, Sweden

Delin, Jenny (författare): Department of Gastroenterology, Ersta Hospital, Stockholm, Sweden,Ersta Hosp, Sweden

Strid, Hans (författare): Department of Internal Medicine, Södra Älvsborgs Hospital, Borås, Sweden,Sodra Alvsborgs Hosp, Sweden

Sjöberg, Mats (författare): Department of Internal Medicine, Skaraborgs Hospital, Lidköping, Sweden,Skaraborgs Hosp, Sweden

Öberg, David (författare): Department of Internal Medicine, Sunderby Hospital, Sunderbyn, Sweden,Sunderby Hosp, Sweden

Bergemalm, Daniel, 1977- (författare): Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Gastroenterology,Orebro Univ, Sweden

Hjortswang, Henrik (författare): Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken

Halfvarson, Jonas, 1970- (författare): Örebro universitet,Institutionen för medicinska vetenskaper,Orebro Univ, Sweden

SWIBREG SVEAH Study Group, - (bidragsgivare)

visa färre...

(creator_code:org_t)

2021-07-03
2021
Engelska.
Ingår i: Therapeutic Advances in Gastroenterology. - : Sage Publications. - 1756-283X .- 1756-2848. ; 14

Relaterad länk:: https://doi.org/10.1...; visa fler...; https://journals.sag...; https://liu.diva-por... (primary) (Raw object); https://urn.kb.se/re...; https://doi.org/10.1...; https://urn.kb.se/re...; http://kipublication...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

Background: Prospectively and systematically collected real-world data on vedolizumab are scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in inflammatory bowel disease (IBD).Methods: This study was a prospective, observational, multicentre study. Overall, 286 patients with active IBD were included (Crohn's disease, n = 169; ulcerative colitis, n = 117). The primary outcomes were clinical response at week 12 and clinical remission at week 52, based on the Harvey Bradshaw Index and the partial Mayo Clinic score. Secondary outcomes included clinical remission at week 12, clinical response at week 52, corticosteroid-free clinical remission at week 52, changes in biochemical measures, and health-related quality of life (HRQoL).Results: At baseline, 88% of the patients were exposed to anti-TNF and 41% of the patients with Crohn's disease had undergone ⩾1 surgical resection. At week 12, clinical response was 27% and remission 47% in Crohn's disease; corresponding figures in ulcerative colitis were 52% and 34%. Clinical response, remission and corticosteroid-free remission at week 52 were 22%, 41% and 40% in Crohn's disease and 49%, 47% and 46% in ulcerative colitis, respectively. A statistically significant decrease in median faecal-calprotectin and C-reactive protein was observed at 12 and 52 weeks in patients with Crohn's disease and ulcerative colitis. The HRQoL measures Short Health Scale and EuroQol 5-Dimensions improved in both Crohn's disease and ulcerative colitis patients (p < 0.001). Clinical disease activity at baseline was inversely associated with clinical remission at week 52.Conclusion: Vedolizumab proved effective for the treatment of refractory IBD in clinical practice.

Hitta via bibliotek

Therapeutic Advances in Gastroenterology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Gastroenterologi

Artiklar i publikationen: Therapeutic Adva ...

Av lärosätet: Örebro universitet; Linköpings universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

Real-world effectiveness of vedolizumab in inflammatory bowel disease : week 52 results from the Swedish prospective multicentre SVEAH study

Ämnesord

Nyckelord

Publikations- och innehållstyp

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Sök utanför SwePub